BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Announces New VP of Broker and Consultant Partnerships

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has appointed Claudia Rimerman Kraut in the newly created role of vice president of broker and consultant partnerships. Kraut comes to her new responsibilities with impressive senior-management experience at Omada Health, American Well, AIG, United Healthcare and Humana. Kraut will lead Dario’s benefit consultant and alliance outreach and be a senior member of DRIO’s employer sales team. Kraut boasts a work record with a unique and notable combination of benefits, partnerships and digital health experience, most recently serving as director of alliances at Omada Health. “We believe that Claudia’s deep expertise and relationships in healthcare and digital therapeutics will strengthen our commercial team and positions us well to accelerate our growth in 2021 and beyond,” DarioHealth president and general manager of North America Rick Anderson stated in the press release. “As demonstrated by our recent announcement of customers won through benefit consultants, we believe relationships with benefits consultancies are a meaningful driver of our long-term growth.  We have had early success working with benefit consultants and we believe that Claudia will help us accelerate and expand our opportunities. We are pleased that someone with Claudia’s record of achievements has joined Dario to lead our broker and consultant relationships.”

To view the full press release, visit https://ibn.fm/EBqEB

About DarioHealth Corp.

DarioHealth is a leading global, digital-therapeutics company revolutionizing how people with chronic conditions manage their health. By delivering evidence-based interventions driven by connected devices, data, high-quality software and coaching, the company makes the right thing to do the easy thing to do. The company’s cross-functional team operates at the intersection of life sciences, behavioral science and software technology. Dario offers one of the highest-rated diabetes and hypertension solutions on the market; its highly engaging, user-centric MyDario(TM) mobile app is used regularly by tens of thousands of consumers worldwide. The company is rapidly expanding into new chronic conditions and geographic markets, using a performance-based approach to improve its users’ health. For more information about the company, please visit www.DarioHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) CEO Named EY Entrepreneur of the Year 2025 Finalist in Established Category 

Nutriband (NASDAQ: NTRB) CEO Gareth Sheridan has been named a finalist in the Established category…

5 days ago

BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Receives FDA Clearance to Begin Trials for CLD-201 in Solid Tumors

Calidi Biotherapeutics (NYSE American: CLDI) announced FDA clearance of its Investigational New Drug application for CLD-201,…

5 days ago

BioMedNewsBreaks – ProPhase Labs Inc. (NASDAQ: PRPH) Closes $23.6M Sale to Focus on Core Businesses

ProPhase (NASDAQ: PRPH), a next-generation biotech, genomics, and diagnostics company, earlier this year announced the…

6 days ago

BioMedNewsBreaks — Bluejay Diagnostics Inc. (NASDAQ: BJDX) Secures $3.7M in Warrant Inducement Transaction 

Bluejay (NASDAQ: BJDX) is a medical technology company developing rapid diagnostics on its Symphony platform…

6 days ago

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Secures Military Contract Extension for Iridium PTT Services

NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, announced that its subsidiary, Global Telesat Communications…

7 days ago

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Announces Positive Data, Continued Advancement of HyBryte(TM)

Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing products to…

1 week ago